Looking at the filing, I have partial balance sheet data. Let me continue reading what's available and construct the article based on confirmed figures.

Ultragenyx Pharmaceutical Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission, disclosing condensed consolidated financial results and updated risk factors for the second quarter.

Key Highlights

  • Shares outstanding: As of July 31, 2026, the registrant had 98,588,873 shares of common stock issued and outstanding.
  • Cash and cash equivalents: Declined to $125 million as of June 30, 2026, from $421 million as of December 31, 2025, according to the filing.
  • Marketable securities (current): Reported at $167 million as of June 30, 2026, compared to $259 million at year-end 2025.
  • Accounts receivable, net: Increased to $200 million as of June 30, 2026, from $158 million as of December 31, 2025.
  • Total current assets: Decreased to $606 million from $951 million at December 31, 2025.
  • Restructuring plan: The company referenced a restructuring plan announced in February 2026, with anticipated savings cited as a forward-looking item subject to uncertainty.

Ultragenyx Reports Declining Cash and Current Assets in Second Quarter 2026

Ultragenyx Pharmaceutical Inc. (Nasdaq Global Select Market: RARE), a Delaware-incorporated biopharmaceutical company headquartered in Novato, California, submitted its Form 10-Q for the quarterly period ended June 30, 2026. The company is classified as a large accelerated filer and confirmed it is not a shell company. The filing covers condensed consolidated financial statements, management's discussion and analysis, and an updated set of risk factors.

According to the condensed consolidated balance sheets included in the filing, cash and cash equivalents stood at $125 million as of June 30, 2026, a decrease from $421 million as of December 31, 2025. Current marketable securities fell to $167 million from $259 million over the same period, while non-current marketable securities rose to $144 million from $57 million. Accounts receivable, net, increased to $200 million from $158 million, and inventory rose to $59 million from $52 million. Total current assets were reported at $606 million, down from $951 million at year-end 2025. Property, plant, and equipment, net, was $235 million as of June 30, 2026, compared to $244 million at December 31, 2025.

The filing contains forward-looking statements, which the company notes are "subject to risks and uncertainties" and made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Among topics addressed in forward-looking statements, the company referenced its expectations for profitability in 2027, the status of regulatory submissions including a resubmitted Biologics License Application for UX111 and a BLA for DTX401, and anticipated savings from a restructuring plan announced in February 2026. The company stated it "assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future."

What Was Disclosed

The 10-Q for the quarter ended June 30, 2026 reported a decline in cash, current marketable securities, and total current assets relative to December 31, 2025, alongside an increase in accounts receivable, non-current marketable securities, and inventory. The company also disclosed pending regulatory submissions and a February 2026 restructuring plan.